139 related articles for article (PubMed ID: 10466627)
1. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease.
Takenaka T; Qin G; Brady RO; Medin JA
Hum Gene Ther; 1999 Aug; 10(12):1931-9. PubMed ID: 10466627
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease.
Takenaka T; Hendrickson CS; Tworek DM; Tudor M; Schiffmann R; Brady RO; Medin JA
Exp Hematol; 1999 Jul; 27(7):1149-59. PubMed ID: 10390190
[TBL] [Abstract][Full Text] [Related]
3. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
[TBL] [Abstract][Full Text] [Related]
4. Preselective gene therapy for Fabry disease.
Qin G; Takenaka T; Telsch K; Kelley L; Howard T; Levade T; Deans R; Howard BH; Malech HL; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3428-33. PubMed ID: 11248095
[TBL] [Abstract][Full Text] [Related]
5. Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector.
Medin JA; Tudor M; Simovitch R; Quirk JM; Jacobson S; Murray GJ; Brady RO
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7917-22. PubMed ID: 8755577
[TBL] [Abstract][Full Text] [Related]
6. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells.
Yoshimitsu M; Higuchi K; Ramsubir S; Nonaka T; Rasaiah VI; Siatskas C; Liang SB; Murray GJ; Brady RO; Medin JA
Gene Ther; 2007 Feb; 14(3):256-65. PubMed ID: 16929352
[TBL] [Abstract][Full Text] [Related]
7. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
8. Retrovirus-mediated transfer of human alpha-galactosidase A gene to human CD34+ hematopoietic progenitor cells.
Takiyama N; Dunigan JT; Vallor MJ; Kase R; Sakuraba H; Barranger JA
Hum Gene Ther; 1999 Dec; 10(18):2881-9. PubMed ID: 10609650
[TBL] [Abstract][Full Text] [Related]
9. Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease.
Sugimoto Y; Aksentijevich I; Murray GJ; Brady RO; Pastan I; Gottesman MM
Hum Gene Ther; 1995 Jul; 6(7):905-15. PubMed ID: 7578409
[TBL] [Abstract][Full Text] [Related]
10. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
11. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector.
Ohsugi K; Kobayashi K; Itoh K; Sakuraba H; Sakuragawa N
J Hum Genet; 2000; 45(1):1-5. PubMed ID: 10697955
[TBL] [Abstract][Full Text] [Related]
12. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy for Fabry disease.
Siatskas C; Medin JA
J Inherit Metab Dis; 2001; 24 Suppl 2():25-41; discussion 11-2. PubMed ID: 11758676
[TBL] [Abstract][Full Text] [Related]
14. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease.
Ziegler RJ; Li C; Cherry M; Zhu Y; Hempel D; van Rooijen N; Ioannou YA; Desnick RJ; Goldberg MA; Yew NS; Cheng SH
Hum Gene Ther; 2002 May; 13(8):935-45. PubMed ID: 12031126
[TBL] [Abstract][Full Text] [Related]
15. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry disease.
Li C; Ziegler RJ; Cherry M; Lukason M; Desnick RJ; Yew NS; Cheng SH
Mol Ther; 2002 Jun; 5(6):745-54. PubMed ID: 12027559
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
[TBL] [Abstract][Full Text] [Related]
18. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.
Miyamura N; Araki E; Matsuda K; Yoshimura R; Furukawa N; Tsuruzoe K; Shirotani T; Kishikawa H; Yamaguchi K; Shichiri M
J Clin Invest; 1996 Oct; 98(8):1809-17. PubMed ID: 8878432
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity.
Ramsubir S; Yoshimitsu M; Medin JA
Mol Ther; 2007 Jun; 15(6):1174-81. PubMed ID: 17387334
[TBL] [Abstract][Full Text] [Related]
20. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
